• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Camurus touts study of depot injection for opioid dependence

May 11, 2021 By Sean Whooley

camurusCamurus announced positive study results for its subcutaneous buprenorphine depot injections (Buvidal) for treating opioid dependence.

Lund, Sweden-based Camurus’ 24-week, randomized, controlled trial compared patient-reported outcomes of opioid dependence treatment with subcutaneous weekly and monthly Buvidal depot injections against daily sublingual buprenorphine. Results were published in JAMA Network Open yesterday.

“The depot evaluation – buprenorphine utilization trial (Debut) results published showed that patients randomized to receive treatment for opioid dependence with weekly or monthly depot buprenorphine injections reported significantly higher and more sustained treatment satisfaction, less treatment burden and higher quality of life ratings than those treated with daily sublingual buprenorphine,” principal investigator and conjoint professor of addiction medicine at the University of Sydney, Australia, Nicholas Lintzeris, said in a news release. “The study’s focus on patient-reported measures better informs patients and clinicians in selecting treatment options than clinical outcomes routinely used in previous studies of opioid dependence treatments.”

The Debut trial randomized 119 patients across six outpatient clinical sites in Australia and observed the primary outcome of global treatment satisfaction through the 14-question Treatment Satisfaction Questionnaire for Medication (TSQM) at the end of the study after 24 weeks.

Debut met its primary endpoint with a significantly higher TSQM global satisfaction score among those who received Buvidal depot injections compared to those who received sublingual buprenorphine. Decreased treatment burden and higher quality of life were also observed as secondary outcomes for the Buvidal group, while the safety profile remained consistent with the known safety profile of buprenorphine, aside from transient, mild-to-moderate injection site reactions.

“This is to our knowledge the first randomized study performed to compare a range of different patient-reported outcomes between a long-acting injection and daily dosing of buprenorphine in the treatment of opioid dependence,” Camurus CMO Dr. Peter Hjelmström said. “The study highlights the use of different patient-reported outcomes as alternate clinical study endpoints and demonstrates the value of Buvidal from a patient’s perspective.”

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: camurus

IN CASE YOU MISSED IT

  • Glucotrack to effect a reverse stock split
  • Medtronic unveils ‘MiniMed’ as name for soon-to-be separated Diabetes unit
  • Insulet, Marvel collab to unveil comic book hero with type 1 diabetes
  • Insulet rolls out new Omnipod 5 iPhone app for use with Dexcom G7
  • Tandem, Abbott strike deal to pair insulin pumps with glucose-ketone monitor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS